The Immunic progressive MS R and D Day is a virtual event hosted by Immunic on Thursday, November 5, 2026, at 12:30 pm ET. The late-stage biotechnology company announced the event on November 2, 2026, as part of its November investor conference schedule. Management will be joined by two experts in multiple sclerosis treatment and new therapy development, Jiwon Oh of the University of Toronto and Maria Pia Sormani of the University of Genoa, Italy, to discuss unmet needs in progressive MS and new approaches that target neurodegeneration and MS progression.
This article is general information only, not medical advice. Multiple sclerosis is a complex neurological condition, and treatment decisions are personal and medical. If you or someone you care for lives with MS, talk to your own doctor about any treatment, trial or research news, rather than making decisions based on a company event or a news article. The Immunic progressive MS R and D Day is an investor and research briefing, not a treatment announcement, and the drug at its center remains investigational.
Table of Contents
Quick Facts
| Detail | What is known |
|---|---|
| Company | Immunic, Inc., Nasdaq ticker IMUX |
| Event | Virtual Progressive Multiple Sclerosis R and D Day |
| Date and time | Thursday, November 5, 2026, at 12:30 pm ET |
| Format | Virtual event, with registration to attend |
| Announced | November 2, 2026, with November investor conferences |
| Expert guests | Jiwon Oh, University of Toronto; Maria Pia Sormani, University of Genoa |
| Lead drug | Vidofludimus calcium, also called IMU-838 |
| Relapsing MS trials | Phase 3 trials underway, top-line data expected by end of 2026 |
| Progressive MS trial | Additional Phase 3 trial initiation expected later in 2026 |
| Drug mechanism | Nurr1 activation plus DHODH inhibition, as described by the company |
| Other November event | Guggenheim 3rd Annual Healthcare Innovation Conference, November 9 to 11 |
What the R and D Day Is For
The Immunic progressive MS R and D Day is a company briefing focused on research, not a product launch. Immunic said the November 5 event will discuss the unmet needs in progressive MS, new approaches to treatment, and its lead program. The company plans to share information about the disease, the trial design for a planned progressive MS Phase 3 study, and the status of its relapsing MS Phase 3 program.
The choice of guests matters here. Jiwon Oh is a neurologist at the University of Toronto, and Maria Pia Sormani is a researcher at the University of Genoa. Their presence signals that the event is meant to include independent clinical and research perspective, not just company management speaking alone. For investors and for patients following research, that mix is useful, because it helps separate company hopes from clinical reality. Still, the Immunic progressive MS R and D Day is hosted by the company, so its framing will naturally favor its own program.
Progressive MS, in Simple Terms
Multiple sclerosis is a condition in which the immune system attacks the protective covering of nerve fibers, which can disrupt signals between the brain and the body. Relapsing MS involves periods of new symptoms or worsening, followed by partial or full recovery. Progressive MS involves a steady worsening of symptoms and disability over time, without clear relapses and remissions, or with progression that continues alongside relapses. That steady progression is what makes progressive MS especially difficult to treat, because therapies that calm relapses do not always stop the slow nerve damage underneath.
This is why researchers focus on neurodegeneration, the gradual loss of nerve cells and function, as a separate target from inflammation alone. A treatment that only reduces inflammation may help with relapses, but it may not slow progression if nerve damage continues. Immunic says its lead drug combines potential neuroprotective effects, linked to activation of a protein called Nurr1, with anti-inflammatory and anti-viral effects linked to inhibition of an enzyme called DHODH. Those are company descriptions of a mechanism, not proof that the drug works in progressive MS. Proof comes only from large, controlled trials.
Where Vidofludimus Calcium Stands
Vidofludimus calcium, also known as IMU-838, is the drug at the center of the Immunic progressive MS R and D Day and Immunic’s lead investigational asset. It is currently in Phase 3 trials for relapsing MS, with top-line data expected by the end of 2026. A separate Phase 3 trial in progressive MS is expected to start later in 2026. The drug is designed to combine two effects: activation of Nurr1, a protein involved in protecting nerve cells, and inhibition of DHODH, an enzyme involved in immune cell activity. The company describes this as a dual mechanism that could both protect nerves and reduce inflammation, which is why it is being tested in progressive MS, where both processes matter.
Readers should therefore treat the Immunic progressive MS R and D Day on November 5 as a progress update, not a result. The relapsing MS top-line data, when it arrives by the end of 2026, will be a much bigger moment for the company and for patients following the program. The progressive MS trial, once it starts, will take much longer to read out, because progression is measured over time. Anyone following this story should watch for trial enrollment details, the specific patient population, and the primary endpoint, which is the main measure the trial uses to judge success.
Why This Event Is Happening Now
Timing is part of the story. The company announced the Immunic progressive MS R and D Day on November 2, 2026, alongside its November investor conference participation, including the Guggenheim 3rd Annual Healthcare Innovation Conference from November 9 to 11. Companies often schedule R and D Days ahead of major data readouts, to educate investors and clinicians about the disease area and the trial design before results arrive. In this case, the relapsing MS top-line data expected by the end of 2026 makes November a natural time to set the stage.
For the broader MS field, progressive MS remains one of the largest unmet needs in neurology. Approved treatments for relapsing MS have improved greatly over the past two decades, but options that clearly slow progression remain limited. That gap is why even a research briefing on progressive MS draws attention from investors, clinicians and patient advocates. It is also why expectations should stay measured. A good R and D Day can explain a science story clearly, but it cannot replace trial data.
What to Watch After November 5
After the Immunic progressive MS R and D Day, three things are worth watching. First, any new detail about the progressive MS Phase 3 trial design, including who can enroll, how long it will run, and what it will measure. Second, any update on the relapsing MS Phase 3 timeline, since top-line data expected by the end of 2026 is the nearest major catalyst. Third, any comment from the expert guests that adds independent context about where progressive MS treatment stands today, and what a meaningful improvement would look like for patients.
Investors will also watch the company cash position and funding plans after the Immunic progressive MS R and D Day, though those were not the focus of the November 2 announcement. Any Phase 3 trial is expensive and takes years, so funding matters for whether Immunic can complete the program. Still, for a general reader, the science and the trial design are the more important parts of the story.
Frequently Asked Questions
What is Immunic Progressive MS R and D Day?
The Immunic progressive MS R and D Day is a virtual research briefing on Thursday, November 5, 2026, at 12:30 pm ET, where Immunic management and two MS experts discuss unmet needs in progressive MS and new therapy approaches.
Is vidofludimus calcium approved for MS?
No. Vidofludimus calcium is an investigational drug in Phase 3 trials for relapsing MS, with a progressive MS Phase 3 trial expected to start later in 2026. It is not an approved treatment.
What is the difference between relapsing and progressive MS?
Relapsing MS involves periods of new or worsening symptoms followed by recovery. Progressive MS involves steady worsening over time, which is harder to treat because it involves ongoing nerve damage as well as inflammation.
Should patients change treatment based on this event?
No. This is general information about the Immunic progressive MS R and D Day, a research event, not medical advice. Talk to your own doctor before changing any treatment, and do not make decisions based on a company briefing.
Sources
PR Newswire published Immunic November 2 announcement, including the November 5 time for the Immunic progressive MS R and D Day, the expert guests and the drug mechanism. TradingView carried the same company announcement, including the Guggenheim conference dates and the drug mechanism.
Final Thoughts
The Immunic progressive MS R and D Day on November 5 is a useful moment to learn about progressive MS, but it should be understood for what it is. It is a research briefing ahead of bigger trial readouts, not a treatment breakthrough on its own. The science it describes, combining neuroprotection with anti-inflammatory effects, addresses a real gap in progressive MS care. Whether that science translates into a drug that helps patients will depend on Phase 3 data, starting with the relapsing MS results expected by the end of 2026. Until then, the most responsible way to follow this story is with interest, patience, and a conversation with your own doctor if it touches your own health.
Read more on the site: Kentucky measles outbreak update and CVS Health split into two companies.
